Vertex Pharmaceuticals Logo

Email this page: News Release

Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

For security reasons, registration is required before you can use this feature.
* Indicates required field